ONC.L - Oncimmune Holdings Plc

LSE - LSE Delayed Price. Currency in GBp
-0.50 (-0.43%)
At close: 4:30PM BST
Stock chart is not supported by your current browser
Previous Close115.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range113.00 - 113.25
52 Week Range100.00 - 150.00
Avg. Volume8,253
Market Cap70.562M
PE Ratio (TTM)N/A
EPS (TTM)-10.40
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est168.50
  • November Top Growth Stocks
    Simply Wall St.9 months ago

    November Top Growth Stocks

    Companies that have significant growth prospects for profitability and returns can add tangible upside to your portfolio. Oncimmune Holdings and APQ Global are examples of many potential outperformers that analystsRead More...

  • PR Newswire9 months ago

    Launch of "Finger Stick" Sample Collection for EarlyCDT®-Lung

    DESOTO, Kan., Nov. 9, 2017 /PRNewswire/ -- Oncimmune USA LLC, the U.S. subsidiary of Oncimmune Holdings plc (AIM:ONC.L), a leading early cancer detection company developing and commercializing its proprietary EarlyCDT® platform technology, today announces its launch of a validated finger stick collection capability for its EarlyCDT®-Lung test. The EarlyCDT®-Lung test is a simple blood test that aids pulmonologists and other physicians in risk assessment and can detect lung cancer up to four years earlier than other methods.  It is also highly cost-effective. "By introducing finger stick blood collection, we have created an option that will increase the speed and simplicity with which the EarlyCDT®-Lung test can be ordered and completed with no loss of performance.

  • We're sorry this is all we were able to find about this topic.